Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Malignant hypercalcaemia
Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Severe symptomatic hypercalcaemia
Marked or rapidly rising calcium with dehydration, oliguria, confusion, coma, arrhythmia, severe vomiting or acute kidney injury is a metabolic cancer emergency.
Action: Use ABCDE assessment and ECG monitoring, confirm calcium while starting carefully reassessed intravenous 0.9% sodium chloride, stop avoidable calcium-raising exposure, involve acute oncology and endocrine or renal teams and give an appropriate antiresorptive after hydration and renal review.
Overview
Recognise calcium-related neurological, renal and cardiac toxicity, restore safe volume, suppress tumour-driven calcium release, identify the biological mechanism and prevent recurrent metabolic deterioration.
Hypercalcaemia in cancer may arise from tumour-secreted PTH-related peptide, extensive osteoclast activation in bone metastases or myeloma, tumour-associated calcitriol excess, or less commonly ectopic PTH. Dehydration, immobility and calcium-raising medicines can amplify the disturbance. The diagnosis is not simply a high corrected value: abnormal albumin and paraproteins can make total calcium misleading, and a patient with known malignancy can have coincident primary hyperparathyroidism. Confirm the biological abnormality, establish severity and obtain a paired PTH early.
Calcium damages several systems simultaneously. It reduces renal concentrating ability, causing polyuria and dehydration; the resulting fall in glomerular filtration further limits calcium clearance. Neuronal excitability falls, producing weakness, somnolence and delirium. Gastrointestinal motility slows, causing anorexia, nausea and constipation. Cardiac repolarisation shortens and companion potassium or magnesium abnormalities can destabilise rhythm. A rapid rise can cause severe symptoms below the conventional extreme threshold, while gradual chronic elevation may appear deceptively tolerated.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA
Initial treatment sequence
A patient with metastatic cancer is confused, dehydrated and oliguric with an adjusted calcium of 3.6 mmol/L and no pulmonary oedema. What is the best initial management?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Initial management restores circulation and protects organs. Use intravenous 0.9% sodium chloride with repeated assessment of pressure, lungs, urine output, sodium and renal function rather than prescribing a fixed large volume for every adult. Older people and those with heart or kidney failure can develop pulmonary oedema and may need slower replacement, critical-care monitoring or renal support. Loop diuretics do not routinely lower calcium and should be used only to treat true fluid overload after intravascular replacement. Stop non-essential calcium, vitamin D, thiazide and other amplifying exposure.
Antiresorptive treatment follows hydration and renal review. Zoledronic acid suppresses osteoclast activity but takes several days to reach maximal effect and can cause kidney injury and delayed hypocalcaemia. A rapid temporary bridge such as calcitonin may be selected for very severe symptoms; denosumab can help selected refractory or bisphosphonate-limited disease; glucocorticoid is mechanism-specific for calcitriol excess, not routine treatment for every cancer. Definitive control requires tumour treatment or an explicit symptom-focused plan. Monitor through the expected nadir and anticipate recurrence rather than judging failure on the first post-infusion day.
Key points
Malignant hypercalcaemia commonly results from PTHrP secretion, osteolytic metastases or myeloma, and less often calcitriol-producing lymphoma; mechanisms may overlap.
Symptoms include thirst, polyuria, dehydration, constipation, nausea, weakness, cognitive change and shortened-QT or rhythm disturbance; severity depends on rate of rise as well as the number.
First-line confirmation is repeat albumin-adjusted calcium, or ionised calcium when protein binding is unreliable, with renal function, phosphate, magnesium and ECG in severe disease.
Measure intact PTH early: malignant hypercalcaemia usually suppresses it, while a non-suppressed result requires a PTH-dependent branch even in known cancer.
First-line acute treatment is carefully reassessed intravenous 0.9% sodium chloride to correct volume depletion; routine loop diuresis is not calcium treatment and is reserved for genuine overload.
After hydration and renal assessment, intravenous zoledronic acid 4 mg over at least 15 minutes is a licensed adult option for tumour-induced hypercalcaemia at an adjusted calcium of at least 3.0 mmol/L.
Antiresorptive effect develops over days, so do not repeat the dose prematurely; severe refractory disease may need calcitonin, denosumab or dialysis through specialist guidance.
Aetiology
01
PTH-related peptide secretion
Squamous and several other tumours secrete PTHrP, increasing renal calcium retention and osteoclastic bone resorption while suppressing endogenous PTH.
02
Osteolytic metastatic disease
Breast cancer, myeloma and other marrow or bone metastases release local cytokines that activate osteoclasts and liberate skeletal calcium.
03
Excess calcitriol production
Some lymphomas and granulomatous tumour-associated processes increase extrarenal calcitriol, enhancing intestinal calcium absorption and bone turnover.
04
Contributing medicines and volume loss
Calcium or vitamin D supplements, thiazides, lithium, dehydration and immobility may amplify a malignant mechanism or reveal a separate cause.
Pathophysiology
1
Renal concentrating failure
High filtered calcium impairs tubular water handling, causing polyuria and thirst; dehydration then reduces filtration and further limits calcium excretion.
2
Neuronal function slows
Raised extracellular calcium reduces membrane excitability, producing fatigue, proximal weakness, cognitive slowing, delirium and eventually coma.
3
Osteoclast activity accelerates
PTHrP and local tumour mediators increase RANK-ligand-driven bone resorption, releasing calcium faster than kidney and skeleton can rebalance it.
4
Electrical and smooth-muscle effects
Repolarisation shortens and rhythm can destabilise, while gastrointestinal smooth muscle slows, contributing to anorexia, nausea, constipation and ileus.
Clinical features and red flags
Volume-depletion cycle
Thirst, polyuria, dry mucosa, postural hypotension and rising creatinine show renal concentrating failure and reduced filtration amplifying the calcium.
Neurocognitive toxicityRed flag
Lethargy, proximal weakness, confusion, agitation, reduced consciousness or seizure reflects important neurological effect and may progress rapidly.
Gastrointestinal slowing
Anorexia, nausea, vomiting, abdominal discomfort, constipation or ileus can dominate and further worsen dehydration and medicine absorption.
Cardiac manifestationRed flag
Shortened QT, bradyarrhythmia, conduction change or syncope is concerning, particularly with digoxin exposure or potassium and magnesium disturbance.
Bone and cancer clue
Focal pain, fracture, anaemia, renal dysfunction or a palpable tumour may identify osteolytic metastasis, myeloma or the underlying malignancy.
Atypical biochemical branch
Non-suppressed PTH, striking vitamin-D abnormality or chronic stable elevation signals a competing or additional mechanism requiring targeted investigation.
Red flags requiring action
Confusion, reduced consciousness, seizure or profound weakness with raised calcium indicates neurological toxicity and needs monitored treatment.
Investigations
01First-line repeat adjusted or ionised calciumFirst stepFirst line
Why
Confirm true elevation, assess trajectory and avoid protein-binding artefact.
Interpretation and limitations
Use ionised calcium when critical illness, abnormal albumin or paraprotein makes adjusted calcium unreliable; compare previous results because speed of rise changes urgency.
02Renal profile, phosphate and magnesium
Why
Quantify volume and organ injury and identify companion electrolytes that constrain treatment.
Interpretation and limitations
Acute kidney injury increases severity and antiresorptive risk; low phosphate can fit PTHrP but is not diagnostic, and magnesium deficiency increases arrhythmia risk.
03Paired intact PTH
Why
Separate PTH-independent malignant physiology from parathyroid-driven hypercalcaemia.
Interpretation and limitations
Suppressed PTH supports malignancy or another independent cause; an inappropriately normal or raised result enters the primary-hyperparathyroidism or lithium pathway.
04ECG and continuous monitoring when severe
Why
Detect repolarisation and rhythm disturbance during acute calcium and fluid change.
Interpretation and limitations
Shortened QT may support calcium effect but a normal ECG does not make severe hypercalcaemia safe; investigate concurrent electrolyte and cardiac causes.
Differential diagnosis
01
Primary hyperparathyroidism
An inappropriately normal or raised PTH during hypercalcaemia indicates a PTH-dependent pathway that can coexist with cancer and needs endocrine evaluation.
02
Medicine or supplement excess
Thiazide, lithium, vitamin D, calcium antacids and vitamin A can raise calcium; chronology and PTH or vitamin-D pattern help assign causality.
03
Granulomatous calcitriol excess
Sarcoidosis, tuberculosis and other granulomatous disease can increase calcitriol and mimic lymphoma-associated hypercalcaemia, requiring infection and inflammatory context.
04
Laboratory or protein-binding artefact
Abnormal albumin, paraprotein and sampling problems can distort total calcium; ionised measurement clarifies biologically active calcium when results and phenotype disagree.
Management
01StabiliseRestore volume without causing overloadFirst stepConfirmed hypercalcaemia causes symptoms, dehydration, renal injury or cardiac concern.+
1Use ABCDE assessment, ECG, neurological examination and accurate fluid balance; repeat calcium and companion electrolytes and stop avoidable calcium-raising medicines and supplements.
2Give intravenous 0.9% sodium chloride in reassessed stages, adapting each prescription to pressure, urine, sodium, lungs, age and cardiac or renal reserve.
3EscalationEscalate shock, severe neurological change, arrhythmia, oliguria or inability to hydrate safely to acute oncology, endocrine, renal and critical-care teams.
02SuppressBlock pathological calcium releaseTrue malignant hypercalcaemia persists and antiresorptive treatment is appropriate.+
Complications
01
Acute kidney injury
Polyuria, vomiting and reduced intake cause volume depletion, while vasoconstriction, stones and myeloma-related injury further reduce filtration.
02
Coma and aspiration
Progressive delirium and reduced consciousness can lead to immobility, aspiration, pressure injury and loss of capacity for cancer decisions.
03
Arrhythmia
Severe calcium elevation and associated potassium or magnesium change can shorten repolarisation and provoke conduction disturbance or ventricular arrhythmia.
04
Recurrent metabolic crisis
Antiresorptive treatment lowers calcium temporarily, but active tumour or untreated calcitriol or PTHrP drive can produce repeated dehydration and admission.
Monitoring and follow-up
During rehydration, record observations, fluid balance, urine output, daily weight, lung examination and sodium and creatinine at a frequency matched to severity.
Repeat adjusted or ionised calcium at clinically appropriate intervals and interpret direction against treatment timing rather than chasing hourly minor change after bisphosphonate.
Check phosphate and magnesium and monitor ECG continuously when calcium, symptoms or companion electrolyte abnormalities create rhythm risk.
After zoledronic acid, monitor renal function and delayed hypocalcaemia through the expected nadir and ensure any repeat dose is a senior specialist decision.
Track tumour response, pain, mobility, fracture and spinal symptoms because metabolic control without cancer or skeletal care is temporary.
Before discharge or symptom-focused care, document hydration advice, stopped medicines, next blood test, owner and exact return symptoms such as confusion, vomiting or reduced urine.
Special situations
Rate changes severity
A rapid calcium rise can cause delirium and kidney injury at a lower concentration than a slowly established chronic elevation.
PTH still matters in cancer
Known malignancy does not make every raised calcium malignant; an unsuppressed PTH redirects the mechanistic investigation.
Saline is active treatment
Correcting renal perfusion interrupts the self-amplifying dehydration cycle and creates safer conditions for antiresorptive therapy.
Bisphosphonate is delayed
Lack of a dramatic calcium fall on the first day is expected and does not justify an immediate repeat nephrotoxic dose.
Recurrence signals active disease
Repeated hypercalcaemia often reflects uncontrolled tumour biology and should prompt honest review of cancer treatment and goals.
Common pitfalls
01
Assigning hypercalcaemia to cancer without confirming the result and measuring paired PTH.
02
Prescribing a fixed large saline volume without repeated cardiac, respiratory and renal assessment.
03
Using a loop diuretic routinely before euvolaemia to force urinary calcium loss.
04
Repeating zoledronic acid early because its delayed antiresorptive effect has not yet peaked.
05
Ignoring hypocalcaemia, phosphate and magnesium decline after antiresorptive treatment.
06
Treating the calcium while missing pathological fracture, MSCC, sepsis or renal obstruction.
07
Discharging after biochemical improvement without a next test, result owner or tumour-control plan.
Treat the underlying cancer and create a recurrence plan that includes calcium, renal and companion electrolyte monitoring, hydration access and goals of care.
Oliguria, rapidly increasing creatinine or inability to tolerate fluid safely requires urgent renal and critical-care input.
Arrhythmia, syncope or a markedly shortened QT with companion potassium or magnesium disturbance increases immediate cardiac risk.
Focal bone pain, inability to weight bear or new spinal neurological features may indicate pathological fracture or MSCC requiring a parallel emergency pathway.
Known cancer must not suppress a second diagnosis: non-suppressed PTH suggests coincident primary hyperparathyroidism or another PTH-dependent cause.
05Mechanism-directed testing
Why
Identify PTHrP, calcitriol, myeloma or medicine-related disease when the answer changes treatment.
Interpretation and limitations
Select PTHrP, vitamin D metabolites, serum electrophoresis, immunofixation and free light chains with specialist input rather than ordering every test indiscriminately.
Choose imaging from symptoms and known disease; correcting calcium does not delay urgent fracture stabilisation or whole-spine MRI for neurological signs.
1
Review renal function, prior bisphosphonate or denosumab exposure, dental and jaw risk, calcium and vitamin-D status and the expected goals of treatment.
2Give the selected intravenous bisphosphonate at its licensed infusion time after hydration and record the expected delayed nadir before considering further treatment.
3For severe refractory or rapidly threatening disease, seek specialist use of calcitonin, denosumab, mechanism-specific glucocorticoid or renal replacement therapy.
03ExplainDefine the biological mechanismHypercalcaemia is new, recurrent, disproportionate or biochemically atypical.+
1Interpret paired PTH before assigning the result to cancer, then review medicines, supplements, hydration, immobility and previous calcium pattern.
2Use myeloma testing, PTHrP, vitamin-D metabolites and targeted imaging only when phenotype and treatment consequences support them.
3Treat coexisting primary hyperparathyroidism, calcitriol excess, obstruction, sepsis or renal injury rather than assuming one malignant mechanism explains every abnormality.
04Prevent recurrenceControl tumour and plan the next calcium checkSymptoms and calcium improve after acute fluid and antiresorptive treatment.+
1Monitor through the expected nadir for kidney injury, hypocalcaemia and phosphate or magnesium decline and assign the next blood test and result owner.
2Coordinate tumour-directed treatment, bone management, hydration support and medicine reconciliation with oncology and primary care.
3Discuss prognosis, future admission and symptom priorities, integrating specialist palliative care when repeated metabolic treatment no longer provides a worthwhile benefit.
Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
Corrects the volume-depletion cycle, restores renal perfusion and increases urinary calcium clearance before delayed antiresorptive benefit develops.
Intravenous 0.9% sodium chloride
Use the staged volume and infusion rate in the current Society for Endocrinology and local acute-oncology pathway, reassessing after each prescription for blood pressure, urine output, sodium, lung signs and cardiac or renal tolerance.
Fixed aggressive volumes can precipitate pulmonary oedema. Do not use routine loop diuresis to force calcium excretion; reserve a diuretic for genuine overload after adequate intravascular replacement.
Inhibits osteoclast-mediated calcium release and provides sustained control after immediate volume correction has started.
Zoledronic acid
For an adult with tumour-induced hypercalcaemia and albumin-corrected calcium at least 3.0 mmol/L, give a single 4 mg intravenous infusion over no less than 15 minutes after adequate hydration and renal assessment.
Check creatinine, calcium, phosphate and magnesium and follow the current product renal instructions. Avoid premature repeat dosing; monitor acute-phase reaction, renal injury, delayed hypocalcaemia and osteonecrosis risk.
Reduces osteoclast activity and renal calcium reabsorption within hours in selected severely symptomatic patients.
Calcitonin rapid bridge
Use the current weight-based specialist subcutaneous or intramuscular acute-hypercalcaemia regimen for a short course when a rapid temporary fall is required while antiresorptive treatment takes effect.
Tachyphylaxis limits effect after the first days, and nausea and hypersensitivity can occur; availability varies and it never replaces hydration or cause treatment.
Reduces excess calcitriol generation in selected lymphoma-associated hypercalcaemia rather than treating every malignant mechanism.
Glucocorticoid for calcitriol-mediated disease
Use the lymphoma- or mechanism-specific oral or intravenous corticosteroid regimen chosen by oncology or endocrinology after infection and diagnostic-tissue considerations are addressed.
Steroid can obscure lymphoma histology and worsen infection, glucose, delirium and muscle weakness; obtain tissue before treatment when stable enough and monitor response biologically.